씨엔티테크 has completed a successful exit from its portfolio company BARC, achieving a threefold return on investment through its sale to 강남약품, a strategic investor in the healthcare sector.

Information on the Target

씨엔티테크, a prominent player in the investment landscape, has successfully completed the exit of its portfolio company, BARC, a specialist brand in functional recovery footwear, on the 20th of this month. BARC was designed with input from specialists in rehabilitation medicine and is known for its ergonomic recovery shoes that cater to wellness needs and healthcare applications.

Over the years, BARC has strengthened its product competitiveness by catering to the hospital and wellness markets. The brand has made significant strides in developing specialized footwear for healthcare professionals, successfully partnering with major hospitals such as Seoul National University Hospital and Severance Hospital, establishing a strong B2B supply reference.

Industry Overview in the Target’s Specific Country

The recovery footwear industry in South Korea is witnessing significant growth, driven by an increasing demand for ergonomic and wellness-focused products. With a growing awareness around health an

View Source

Similar Deals

DKSH Molecular Diagnostics Korea Inc. (MDxK)

2025

Buyout In-Vivo Diagnostic & Testing Substances South Korea
DKSH Molecular Diagnostics Korea Inc.

2025

Buyout Bio Diagnostics & Testing South Korea
DKSH MDxK

2025

Buyout In-Vivo Diagnostic & Testing Substances South Korea
Lunit Prognosia

Buyout Bio Diagnostics & Testing South Korea
ARCHIMED Jeisys Medical

Buyout Advanced Medical Equipment & Technology (NEC) South Korea
Bambu Ventures Lemonaid Health

2026

Buyout Advanced Medical Equipment & Technology (NEC) United States of America

강남약품

invested in

바크(BARC)

in 2023

in a Buyout deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert